Determination of Purlin R-factors Using a Non-linear Analysis

In both Australia and the U.S.A., the design procedure for purlins under wind uplift loading is based on the use of reduction factors (R-factors), which allow for the flexural-torsional or nonlinear twisting behaviour of purlins with screw-fastened sheeting. To date, all R-factors have been determined by testing. However, in the future it may be more efficient to obtain R-factors from numerical models to minimise testing. This paper shows how a numerical model of the twisting behaviour of channel and Z-section purlins can be used to generate R-factors. Comparisons between experimentally determined and numerically based R-factors are made

USE OF INHALANT ANESTHETICS IN THREE SNAKE SPECIES

Different snake species respond differently to various anesthetic agents. Hence, an anesthetic procedure developed for one species cannot necessarily be safely transferred to another species. The goal of this paper is to summarize our experience using inhalant anesthetics on three snake species, including both procedures that were successful and those we found to be less satisfactory. We found isoflurane delivered with a precision vaporizer to be the best agent to anesthetize black rat snakes (Elaphe o. obsoleta). Sex and mass did not seem to affect induction times in black rat snakes, but larger female rat snakes recovered faster from anesthesia than smaller females. Halothane delivered in the open method provided consistent anesthesia in northern water snakes (Nerodia s. sipedon), although it caused some mortality and should not be used on debilitated patients. Halothane delivered with a precision vaporizer may be used to anesthetize eastern massasauga rattlesnakes (Sistrurus c. catenatus). However, care must be taken to prevent mortality resulting from anesthetic overdose. Sex and mass had no effect on induction and recovery times in the rattlesnakes, but stressed animals require longer induction and recovery times

Changing the Shape of Sickle Cell Disease Treatment: A Hermeneutic Study of a Case that Changed a Family and a Medical Practice

This hermeneutic study analyzes a case of one family who chose to undergo two hematopoietic stem cell transplants for two of their four children affected with sickle cell disease (SCD) with full knowledge of the risks involved with curative therapy. This case had a life-changing impact on the family and on the medical practice of the physician who worked with them. As a result of this family, international treatment of early transplant for SCD has adopted different protocols. In this study, interviewing the mother in the family, the physician, and the transplant nurse, and analyzing the data hermeneutically brings us to a deeper understanding of how change occurs and its profound effect on lives and medical treatment.

Show me the numbers: what data currently exist for non‐native species in the USA?

Non‐native species continue to be introduced to the United States from other countries via trade and transportation, creating a growing need for early detection and rapid response to new invaders. It is therefore increasingly important to synthesize existing data on non‐native species abundance and distributions. However, no comprehensive analysis of existing data has been undertaken for non‐native species, and there have been few efforts to improve collaboration. We therefore conducted a survey to determine what datasets currently exist for non‐native species in the US from county, state, multi‐state region, national, and global scales. We identified 319 datasets and collected metadata for 79% of these. Through this study, we provide a better understanding of extant non‐native species datasets and identify data gaps (ie taxonomic, spatial, and temporal) to help guide future survey, research, and predictive modeling efforts

Fluticasone furoate/vilanterol (100/25; 200/25 μg) improves lung function in COPD: a randomised trial.

SummaryBackgroundOnce-daily combination treatment is an attractive maintenance therapy for COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is unknown. We compared two strengths of fluticasone furoate (FF) plus vilanterol (VI), the same strengths of the individual components, and placebo.MethodsMulticentre, randomised, 24-week, double-blind, placebo-controlled, parallel-group study in stable, moderate-to-severe COPD subjects (N = 1224). Subjects were randomised to FF/VI (200/25 μg; 100/25 μg), FF (200 μg; 100 μg), VI 25 μg, or placebo, once daily in the morning. Co-primary efficacy endpoints; 0–4 h weighted mean (wm) FEV1 on day 168, and change from baseline in trough (23–24 h post-dose) FEV1 on day 169. The primary safety objective was adverse events (AEs).ResultsThere was a statistically significant (p < 0.001) increase in wm FEV1 (209 ml) and trough FEV1 (131 ml) for FF/VI 200/25 μg vs. placebo; similar changes were seen for FF/VI 100/25 μg vs. placebo. Whereas the difference between FF/VI 200/25 μg and VI 25 μg in change from baseline trough FEV1 (32 ml) was not statistically significant (p = 0.224), the difference between FF/VI 200/25 μg and FF 200 μg for wm FEV1 (168 ml) was significantly different (p < 0.001). VI 25 μg significantly improved wm and trough FEV1 vs. placebo (209 ml and 131 ml, respectively). No increase was seen in on-treatment AEs or serious AEs (SAEs), with active therapy vs. placebo.ConclusionsFF/VI provides rapid and significant sustained improvement in FEV1 in subjects with moderate-to-severe COPD, which was not influenced by the dose of FF. These data suggest that FF/VI may offer clinical efficacy in COPD and warrants additional study.GSK study number: HZC112207.ClinicalTrials.gov: NCT01054885